Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-621-7722
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$346.64 million
Profitability
Miscellaneous
Employees515
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions
What is Ironwood Pharmaceuticals' stock symbol?
Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."
How were Ironwood Pharmaceuticals' earnings last quarter?
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its earnings results on Tuesday, July, 30th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.15. The biotechnology company earned $102.22 million during the quarter, compared to analyst estimates of $89.28 million. The company's quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.22) EPS. View Ironwood Pharmaceuticals' Earnings History.
When is Ironwood Pharmaceuticals' next earnings date?
What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?
Ironwood Pharmaceuticals issued an update on its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $374.63 million.
What price target have analysts set for IRWD?
11 analysts have issued twelve-month target prices for Ironwood Pharmaceuticals' stock. Their forecasts range from $12.00 to $20.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $15.05 in the next year. This suggests a possible upside of 66.5% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.
What is the consensus analysts' recommendation for Ironwood Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.
Has Ironwood Pharmaceuticals been receiving favorable news coverage?
Press coverage about IRWD stock has been trending neutral this week, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Ironwood Pharmaceuticals.
Who are some of Ironwood Pharmaceuticals' key competitors?
Some companies that are related to Ironwood Pharmaceuticals include Amarin (AMRN), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), GW Pharmaceuticals PLC- (GWPH), United Therapeutics (UTHR), FibroGen (FGEN), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Allakos (ALLK) and Reata Pharmaceuticals (RETA).
What other stocks do shareholders of Ironwood Pharmaceuticals own?
Who are Ironwood Pharmaceuticals' key executives?
Ironwood Pharmaceuticals' management team includes the folowing people:
- Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 55)
- Mr. Thomas A. McCourt, Pres (Age 62)
- Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 46)
- Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 49)
- Dr. Christopher I. Wright, Chief Devel. Officer & Sr. VP of Global Devel.
How do I buy shares of Ironwood Pharmaceuticals?
Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ironwood Pharmaceuticals' stock price today?
One share of IRWD stock can currently be purchased for approximately $9.04.
How big of a company is Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals has a market capitalization of $1.41 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.
What is Ironwood Pharmaceuticals' official website?
How can I contact Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]
MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
